News
| 4 min read
The FDA’s National Priority Voucher program aims to cut standard review times from potentially years to months, raising questions about safety, access, and public health impact.
| 4 min read
FDA guidance now limits routine tissue biopsies, forcing researchers to rethink how blood biopsies can be optimized to reveal tissue biology.
| 3 min read
A physics-based urine test shows early promise in detecting bladder cancer recurrence without invasive procedures.
| 3 min read
Phase 2 trial shows that a topical drug rapidly reduces malodor, pain, and improves quality of life for patients with malignant fungating wounds.
| 4 min read
Preclinical systems such as patient-derived xenografts are providing unprecedented insight into tumor biology and helping bridge the gap between discovery and clinical translation.
| 8 min read
As nearly 90 percent of drugs fail in human trials, researchers are turning to patient-derived cells, engineered tissues, and AI to better predict human responses and reduce costly late-stage failures.
| 4 min read
Investments in solid tumor targets and autoimmune disease, success for a peanut allergy patch, a promising CAR T cell therapy for stiff person syndrome, and more led the news this week.
| 5 min read
Pioneering transplants from pigs to humans could mark a turning point for organ replacement.
| 3 min read
As therapies grow more complex, inactive ingredient innovation is needed to improve drug impact and access.
| 2 min read
New study uses simulations and machine learning to identify a single, high-impact interaction within a viral fusion protein, highlighting a potential new target for antiviral drug development.
| 9 min read
Rather than replacing radiologists, AI is working alongside them to catch cancers earlier and improve screening efficiency.
| 4 min read
Billion-dollar partnerships, Phase 1 wins, AI regulatory tools, and more led the news this week.
